Lung Cancer Dispatch
Follow
Find tag "monitoring"
3.6K views | +2 today
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

General Oncology - Six-Gene Signature Predicts Survival After Targeted Therapy for NSCLC

General Oncology - Six-Gene Signature Predicts Survival After Targeted Therapy for NSCLC | Lung Cancer Dispatch | Scoop.it

"The presence of a six-gene profile in the microRNA of patients with advanced non-squamous non-small-cell lung cancer (NSCLC) predicts reduced survival likelihood after first-line treatment with targeted therapy followed by chemotherapy for disease progression, indicate research results.


"While the findings 'should be further validated', the researchers believe their analysis 'supports the hypothesis that circulating [microRNA's] may further be developed as predictive markers for EGFR-targeted treatment' in an NSCLC population whose response to epidermal growth-factor receptor (EGFR) tyrosine kinase inhibitors is unknown."


Editor's note: This story describes a new, blood test-based method by which oncologists may be able to predict the effects of targeted therapy treatment on the survival of patients with non-squamous non-small cell lung cancer (NSCLC). Specifically, it may be able to predict the effects of first-line treatment with drugs known as EGFR inhibitors, which are prescribed to people whose tumors have mutations in the EGFR gene, as detected by molecular testing. In a study with volunteer patients, scientists took blood samples just before and just after the patients began taking the drugs bevacizumab or erlotinib. The scientists identified six different kinds of a molecule called microRNA that, if present, were associated with a lower chance of survival (29 months versus more than 45 months). More testing will be needed to determine if this six-gene signature can be used widely; it would be a non-invasive alternative to making predictions and monitoring treatment effectiveness using repeat tumor biopsies.

Cancer Commons's insight:

medwireNews  |  June 20, 2014

more...
No comment yet.
Rescooped by Cancer Commons from Melanoma Dispatch
Scoop.it!

DNA Shed by Tumors Shows Promise for Non-Invasive Screening and Prognosis

DNA Shed by Tumors Shows Promise for Non-Invasive Screening and Prognosis | Lung Cancer Dispatch | Scoop.it

"Certain fragments of DNA shed by tumors into the bloodstream can potentially be used to non-invasively screen for early-stage cancers, monitor responses to treatment and help explain why some cancers are resistant to therapies, according to results of an international study led by Johns Hopkins Kimmel Cancer Center investigators.


"Analyzing blood samples from 640 patients with various cancers, the researchers used digital polymerase chain reaction-based technology (a sophisticated method of multiplying and measuring the number DNA molecules) to evaluate how well the DNA fragments predicted the presence of tumors in the patients."

Cancer Commons's insight:

Medical Xpress  |  Mar 6, 2014

more...
Cancer Commons's curator insight, March 6, 11:39 AM

Medical Xpress  |  Mar 6, 2014

Cancer Commons's curator insight, March 6, 11:39 AM

Medical Xpress  |  Mar 6, 2014

Scooped by Cancer Commons
Scoop.it!

Blood Test Accurate in Later Stage Lung Cancer Diagnosis

Blood Test Accurate in Later Stage Lung Cancer Diagnosis | Lung Cancer Dispatch | Scoop.it

"Simple blood tests for cancer diagnosis and post-treatment assessment are getting closer all the time. New research has shown that a new assay for measuring circulating tumor DNA (ctDNA) could detect essentially all stage II-IV non-small-cell lung cancers (NSCLC), and is even about 50% sensitive in finding stage I NSCLC as well."


" 'Analysis of ctDNA has the potential to revolutionize detection and monitoring of tumors,' wrote investigators led by senior study author Maximilian Diehn, MD, PhD, of Stanford University School of Medicine, in Nature Medicine. 'Noninvasive access to cancer-derived DNA is particularly attractive for solid tumors, which cannot be repeatedly sampled without invasive procedures.' "

Cancer Commons's insight:

Cancer Network  |  Apr 24, 2014

more...
No comment yet.